Incannex Healthcare (Nasdaq: IXHL) is a clinical-stage biopharmaceutical company developing cannabinoid and psychedelic therapies for unmet mental-health and inflammatory conditions. Its lead psychedelic asset, PSX-001, is an oral synthetic psilocybin therapy for generalized anxiety disorder; the company reported Phase 2 data showing a 12.8-point HAM-A anxiety reduction versus 3.6 points for placebo, with a 27% remission rate sustained through 11 weeks. Incannex holds an active U.S. IND for the program and has positioned it within the 2026 federal push to accelerate access to psychedelic treatments for serious mental illness.
Incannex Healthcare News 27 articles
- Incannex says its PSX-001 psilocybin program aligns with the executive order
- Incannex announces 1-for-30 reverse stock split to maintain Nasdaq listing
- Incannex reports positive Phase 2 results for PSX-001 psilocybin therapy in generalized anxiety disorder
- Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL)
- Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates
- Incannex Healthcare Announces Strategic Financing for up to $60 Million with Arena Investors
- Incannex Healthcare : Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL 42X Form 8 K
- Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
- Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder
- Incannex Healthcare Inc. Quarterly Update, Q1 2024
- Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder
- Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis
- Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences
- Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
- Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia
- Incannex Healthcare Announces Completion of its Redomiciliation to the United States
- Federal Court of Australia Approves Incannex’s Re-Domiciliation and Lodgement of Court Orders With ASIC
- Incannex Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference – September 11-13, 2023
- Incannex to Prepare FDA IND Application for Psilocybin-assisted Psychedelic Psychotherapy Program, Known as Psi-GAD
- Incannex Healthcare June 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement
- Incannex Announces Intention to Redomicile to United States, List all Shares on Nasdaq
- Incannex Announces Participation at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference June 26, 2023
- Incannex Company Presentation – Presentation of Psychennex, Psychedelic Therapies Subsidiary Company
- Incannex Announces Final Results from Phase 1 Clinical Trial Assessing Safety and Pharmacokinetics of IHL-675A
- Incannex Engages Catalent for Development and cGMP Manufacture of Psilocybin Drug Product for Clinical Trials and Potential Commercial Use
- Incannex Engages Catalent for Development and cGMP Manufacture of Psilocybin Drug Product for Clinical Trials and Potential Commercial Use
- Incannex Healthcare Quarterly Activities Report and Appendix 4C Cash Flow Statement